Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPT-0118 Alone and with Pembrolizumab in Advanced Solid Tumors
NCT04859777Phase 1Unknown
- Sponsor
- Monopteros Therapeutics Inc.
- Start
- Apr 2021
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of MPT-0118 in solid tumor (3 arms), sponsored by Monopteros Therapeutics Inc. Primary endpoints: Maximum Tolerated Dose or Recommended Phase 2 Dose at 28 days, Treatment-Emergent Adverse Events at 1 year and 3 more. Status: unknown.
02
Drugs
MPT-0118
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04859777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04859777.